O uso de psilocibina é eficaz no tratamento de depressão?
Edson Santana Gois Filho, Ana Letícia Fiscina Reis, Marco Antonio Galvão Martins de Farias, João Pedro Carvalho Fonseca, Rafael Silva Clímaco, Rafael Baquit Campos
Brazilian Journal of Health Review July 3, 2023 DOI: 10.34119/bjhrv6n4-010 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Citations | 1 |
| Key findings | The text states that SSRIs have been first-line depression treatment since the 1980s, and that psilocybin, an alkaloid from Psilocybe spp. acting as a 5-HT2A receptor agonist, has shown efficacy in improving depression in patients. It frames psychedelic research as an emerging area for new pharmacological therapies. |
Abstract
Os Inibidores da Recaptação de Serotonina (ISRS) foram descobertos na década de 1980 e, desde então, são a primeira linha para o tratamento da depressão. Nos últimos anos, pesquisas para busca de novas terapias farmacológicas vem tomando visibilidade com a descoberta dos efeitos antidepressivos dos psicodélicos. Dentro deles, destaca-se a Psilocibina, um alcalóide advindo do fungo Psilocybe spp., que apresenta ação agonista do receptor serotoninérgico 5-HT2A e mostrou-se eficaz na melhora do quadro de pacientes que sofrem de depressão.
Citations in the library
Cites 5
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up Journal of Psychopharmacology February 1, 2022
- Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects Clinical Pharmacology & Therapeutics November 7, 2021
- Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants Psychopharmacology January 11, 2021
- Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry Pharmacopsychiatry January 19, 2022